Skip to main content

ORIGINAL RESEARCH article

Front. Med.

Sec. Intensive Care Medicine and Anesthesiology

Volume 12 - 2025 | doi: 10.3389/fmed.2025.1549619

Palonosetron versus Tropisetron with Dexamethasone for Prevention of Postoperative Nausea and Vomiting in Pediatric Adenotonsillectomy: A Single Center, Randomized Controlled Trial

Provisionally accepted
Hualin Chen Hualin Chen Liping Sun Liping Sun Jijian Zheng Jijian Zheng Hongbin Gu Hongbin Gu *
  • Department of Anesthesiology, Shanghai Children’s Medical Center, Shanghai, China

The final, formatted version of the article will be published soon.

    Background: Postoperative nausea and vomiting (PONV) remain significant complications following pediatric adenotonsillectomy. Although palonosetron, a second-generation 5-HT3 receptor antagonist, has shown potential for preventing PONV, further research is needed to assess its efficacy when combined with dexamethasone in pediatric otolaryngologic procedures. This study aims to observe the efficacy of palonosetron or tropisetron combined with dexamethasone in preventing PONV in children undergoing adenotonsillectomy. Methods: We enrolled 110 children scheduled for elective adenotonsillectomy under general anesthesia. Based on a computer-generated random number table, children were assigned in equal proportions to receive either palonosetron or tropisetron. The P-group received palonosetron (1 2 / 18 µg/kg, maximum 50 µg), while the T-group received tropisetron (0.1 mg/kg, maximum 2 mg) 5 minutes before anesthesia induction. After receiving their allocated drug, children received intravenous dexamethasone (0.15 mg/kg, maximum 5 mg) during induction. Primary outcomes included PONV incidence at 6, 24, and 48 hours postoperatively. Secondary outcomes included the number of children with PONV scores of 1, 2, and 3, rescue antiemetic medication, and adverse events. Results: A total of 110 children (aged 3-12 y, ASA physical status 1 or 2, weighted 14.3-47.3 kg) were enrolled in the study between December 2021 and July 2023. The P-group (n=52) demonstrated significantly lower PONV incidence than the T-group(n=51) during the 0-48 hours (5.8% vs. 25.5%, P<0.05). Notably, this difference was most pronounced during the first 24 hours: 0-6 hours (0% vs. 10%, P<0.05) and 6-24 hours (3.8% vs. 7.8%, P<0.05). The difference during 24-48 hours was insignificant (4% vs. 8%, P>0.05). Transient junctional rhythm occurred in three patients receiving tropisetron, which did not affect circulation. Headache and dizziness were similar between groups within 48 hours (P-group: 3.8%, T-group: 7.8%, P >0.05). Conclusion: In paediatric adenotonsillectomy, palonosetron with dexamethasone gives better PONV prevention than tropisetron with dexamethasone, especially in the first 24 hours, with comparable safety.

    Keywords: PONV, Palonosetron, Tropisetron, Children, adenotonsillectomy, Clinical Trial Registration: ChiCTR2100046848

    Received: 21 Dec 2024; Accepted: 20 Mar 2025.

    Copyright: © 2025 Chen, Sun, Zheng and Gu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Hongbin Gu, Department of Anesthesiology, Shanghai Children’s Medical Center, Shanghai, 200000, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more